[1] HERNANDEZ R K, WADE S W, REICH A, et al.Incidence of bone metastases in patients with solid tumors:analysis of oncology electronic medical records in the United States[J].BMC Cancer, 2018, 18(1):44.
[2] BOUHASSIRA D, LUPORSI E, KRAKOWSKI I.Prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer[J].Pain, 2017, 158(6):1118-1125.
[3] 王院春,羊璞,惠建荣,等.中医外治法治疗癌性疼痛的临床研究[J].世界中医药, 2021, 16(14):2207-2210.
[4] BENNETT M I.Mechanism-based cancer-pain therapy[J].Pain, 2017, 158(Sup 1):S74-S78.
[5] ZAJĄCZKOWSKA R, KOCOT-KĘPSKA M, LEPPERT W, et al.Bone pain in cancer patients:mechanisms and current treatment[J].Int J Mol Sci, 2019, 20(23):6047.
[6] YONEDA T, HIASA M, NAGATA Y, et al.Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain[J].Biochim Biophys Acta BBA Biomembr, 2015, 1848(10):2677-2684.
[7] BASBAUM A I, BAUTISTA D M, SCHERRER G, et al.Cellular and molecular mechanisms of pain[J].Cell, 2009, 139(2):267-284.
[8] HO K W, WARD N J, CALKINS D J.TRPV1:a stress response protein in the central nervous system[J].Am J Neurodegener Dis, 2012, 1(1):1-14.
[9] NIIYAMA Y, KAWAMATA T, YAMAMOTO J, et al.Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons[J].Neuroscience, 2007, 148(2):560-572.
[10] GHILARDI J R, RÖHRICH H, LINDSAY T H, et al.Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain[J].J Neurosci, 2005, 25(12):3126-3131.
[11] NIIYAMA Y, KAWAMATA T, YAMAMOTO J, et al.SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain[J].Br J Anaesth, 2009, 102(2):251-258.
[12] YU Y, CHEN Z, LI W G, et al.A nonproton ligand sensor in the acid-sensing ion channel[J].Neuron, 2010, 68(1):61-72.
[13] NAGAE M, HIRAGA T, YONEDA T.Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization[J].J Bone Miner Metab, 2007, 25(2):99-104.
[14] CRAIG A D.Distribution of brainstem projections from spinal lamina I neurons in the cat and the monkey[J].J Comp Neurol, 1995, 361(2):225-248.
[15] HAO S L, LIU S E, ZHENG X X, et al.The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats[J].Neuropsychopharmacology, 2011, 36(3):664-676.
[16] ZHANG J, WANG L P, WANG H S, et al.Neuroinflammation and central PI3K/Akt/mTOR signal pathway contribute to bone cancer pain[J].Mol Pain, 2019, 15:1744806919830240.
[17] HASUE F, KUWAKI T, KISANUKI Y Y, et al.Increased sensitivity to acute and persistent pain in neuron-specific endothelin-1 knockout mice[J].Neuroscience, 2005, 130(2):349-358.
[18] HASUE F, KUWAKI T, YAMADA H, et al.Inhibitory actions of endothelin-1 on pain processing[J].J Cardiovasc Pharmacol, 2004, 44(Sup 1):S318-S320.
[19] HAN M M, YANG C W, CHEUNG C W, et al.Blockage of spinal endothelin A receptors attenuates bone cancer pain via regulation of the Akt/ERK signaling pathway in mice[J].Neuropeptides, 2018, 68:36-42.
[20] HANS G, DESEURE K, ADRIAENSEN H.Endothelin-1-induced pain and hyperalgesia:a review of pathophysiology, clinical manifestations and future therapeutic options[J].Neuropeptides, 2008, 42(2):119-132.
[21] STÖSSER S, SCHWEIZERHOF M, KUNER R.Hematopoietic colony-stimulating factors:new players in tumor-nerve interactions[J].J Mol Med, 2011, 89(4):321-329.
[22] SCHWEIZERHOF M, STÖSSER S, KUREJOVA M, et al.Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain[J].Nat Med, 2009, 15(7):802-807.
[23] TURHAN A B, BINAY C, BOR O, et al.The effects of short-term use of granulocyte colony-stimulating factor on bone metabolism in child cancer patients[J].North Clin Istanb, 2018, 5(4):277-281.
[24] SAGAR D R, NWOSU L, WALSH D A, et al.Dissecting the contribution of knee joint NGF to spinal nociceptive sensitization in a model of OA pain in the rat[J].Osteoarthr Cartil, 2015, 23(6):906-913.
[25] MANTYH P W.Bone cancer pain:from mechanism to therapy[J].Curr Opin Support Palliat Care, 2014, 8(2):83-90.
[26] BLAIR J M, ZHOU H, SEIBEL M J, et al.Mechanisms of Disease:roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis[J].Nat Clin Pract Oncol, 2006, 3(1):41-49.
[27] LIPTON A, ALI S M, LEITZEL K, et al.Serum osteoprotegerin levels in healthy controls and cancer patients[J].Clin Cancer Res, 2002, 8(7):2306-2310.
[28] ROUDIER M P, BAIN S D, DOUGALL W C.Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats[J].Clin Exp Metastasis, 2006, 23(3):167-175.
[29] BLOOM A P, JIMENEZ-ANDRADE J M, TAYLOR R N, et al.Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers[J].J Pain, 2011, 12(6):698-711.
[30] SEVCIK M A, GHILARDI J R, PETERS C M, et al.Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization[J].Pain, 2005, 115(1/2):128-141. |
